Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.48 |
| ▸ | JAK2 | O60674 | 8/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 7/20 | 0.37 |
| ▸ | TYK2 | P29597 | 7/20 | 0.37 |
| ▸ | JAK3 | P52333 | 7/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356410 | 0.91 | ALK (0.56) | ALKJAK2SLC40A1JAK1TYK2 | |
| SCHEMBL13633182 | 0.91 | ALK (0.47) | ALKJAK2SLC40A1PKMJAK1 | |
| SCHEMBL4354484 | 0.87 | ALK (0.57) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL13634001 | 0.86 | ALK (0.50) | ALKJAK2SLC40A1JAK1TYK2 | |
| Trifluoroacetic Acid SCHEMBL4363075 | 0.85 | ALK (0.49) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4359039 | 0.84 | ALK (0.57) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4356599 | 0.84 | ALK (0.57) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4353632 | 0.83 | ALK (0.56) | ALKJAK2JAK1TYK2JAK3 | |
| SCHEMBL4366970 | 0.83 | ALK (0.54) | ALKJAK2SLC40A1JAK1TYK2 | |
| SCHEMBL4363117 | 0.82 | ALK (0.55) | ALKJAK2SLC40A1JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885JAK2 1/4885SLC40A1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.